Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 28, 2026; 32(12): 116953
Published online Mar 28, 2026. doi: 10.3748/wjg.v32.i12.116953
Published online Mar 28, 2026. doi: 10.3748/wjg.v32.i12.116953
From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control
Qing Chen, Department of Scientific Research and Education, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Kang-Ning Li, Graduate School, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Tian-Qi Liu, Department of General Surgery, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Co-first authors: Qing Chen and Kang-Ning Li.
Author contributions: Chen Q contributed to writing the manuscript and literature review; Li KN contributed to writing and editing the manuscript; Liu TQ designed the overall concept and outline of the manuscript, reviewed and edited the manuscript.
Supported by the Medical and Health Appropriate Technology Development and Promotion Project of the Health Commission of Guangxi Zhuang Autonomous Region, No. S2023034.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Tian-Qi Liu, MD, Professor, Department of General Surgery, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, No. 85 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. ljrqt@126.com
Received: November 25, 2025
Revised: December 29, 2025
Accepted: January 9, 2026
Published online: March 28, 2026
Processing time: 114 Days and 9.9 Hours
Revised: December 29, 2025
Accepted: January 9, 2026
Published online: March 28, 2026
Processing time: 114 Days and 9.9 Hours
Core Tip
Core Tip: This editorial highlights vonoprazan-amoxicillin dual therapy, particularly the 0.5 g four-times-daily regimen, as a highly effective, safe, and well-tolerated strategy for Helicobacter pylori eradication, based on a recent large-scale regional trial. Its exceptional cost-effectiveness, high patient compliance, and dosing simplicity position it as a transformative candidate for large-scale public health interventions that aimed at reducing the burden of Helicobacter pylori-associated diseases, including gastric cancer. Successful implementation, however, necessitates addressing challenges such as antimicrobial resistance surveillance and ensuring equitable access to healthcare systems.